ASIAN-CLASSIC第三次专家讨论会议于2010年1月在香港召开，与会专家积极地讨论了第二稿的内容。
Professor Jiguang Wang gave a detailed introduction to the 2nd draft of ASIAN-CLASSIC which mainly consisted of 5 parts including introduction, AMBP lowering trials, prevention of target organ protection trials, prevention of CV events, perspectives & conclusion. All participating professors gave their valued suggestions to the draft and the modifications agreed upon are as follows:
王继光教授对ASIAN-CLASSIC会议的第二次草案作了详细介绍。该草案主要由5部分组成，包括序言、动态血压（AMBP）下降试验、靶器官保护试验、心血管（CV）事件的预防、展望和结论。所有与会教授都对本次草案提出了宝贵建议，最终商定的一致修改意见如下：
1, The blood pressure reduction trials can be shown in two slopes in which the X is the baseline BP and the Y is the BP reduction. When we test the difference of CCBs and ACEI/ARBs in both the slope and the distribution, it should be different in the highly salt sensitive Asian patients.
血压降低试验可以用两个斜率表示，其中X为基线血压，Y代表血压下降值。可以检验钙拮抗剂（CCBS）和血管紧张素转换酶抑制剂/血管紧张素受体拮抗剂(ACEI/ARBs)在斜率和分布上的差异。
2, Add reduction of BP in another column in Table 1 and a small part comparing the night blood pressure, which is more important for the occurrence of stroke.
在表1另一栏里增加血压下降值和一小部分夜间血压比较结果，这些数据对卒中的发生更为重要。
3, Describing briefly the types/pharmacokinetics/indications of major CCBs in a table or a separate part , especially the half life and indications of different CCBs. Drug holiday or missing dose can be mentioned.
使用表格对主要钙拮抗剂（CCBs）的类型/药代动力学/适应证进行简要描述，或者将其单独分列，特别是不同CCBs的半衰期和适应证。本部分可以提及药物假期（drug holiday）或缺失剂量（missing dose）。
4, Add: “5/3mmHg 24h BP difference is very important and may account for 20% further reduction of stroke.”
增加“5/3mmHg的24小时血压差异非常重要，或许这可以说明卒中发生率进一步降低20％的原因”。
5, Table 3: list BP difference and main result of trials. Test the outcome trials in Prof. Staessen’s meta-regression diagram to see if the Asian trials fit into the slope.
表3：列出血压差异和主要试验结果。使用 Staessen教授的荟萃回归分析图对试验结果进行检验，以观察亚洲试验是否与斜率吻合。
6, Add a section on tolerability including compliance and convenience of use of CCBs verses other drugs. Ankle edema happens more frequently in white and black people. Influence on heart rate by different CCBs can be mentioned to explain the difference in MI prevention. And the fact that CCBs don’t have compelling restrictions is very important.
增加耐受性方面的内容，包括相对于其他药物来说，使用CCBs的依从性和便利性情况。踝关节水肿在白种人和黑色人种中发生得更为频繁。本部分内容中可以列出不同的CCBs对心率的影响，以解释在不同的CCB在心肌梗死（MI）预防上的差异。此外，CCBs无强制限制的事实非常重要。
7, Add “unless for compelling indications” in the conclusion part where CCBs are recommended as the preferred first line therapy for most hypertensive patients in Asia. Mention “preferred drug not only for single drug treatment, but also for basis of combination therapy”.
在结论部分“建议将CCBs作为大多数亚洲高血压患者的首选一线治疗药物”处增加“除了强适应证外”。应指明“不仅作为单药治疗的首选药物，而且是联合治疗的基础用药。”
